ArticleEULAR rheumatology open2025
High acceptance and reported efficacy of cannabis for pain management in patients with rheumatic diseases in Germany: a postlegalisation survey.
Article in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Cannabis legalisation in North America has led to increased use of medical cannabis (MC) among patients with inflammatory rheumatic diseases (IRDs). In Europe, there are still no epidemiologic data on the patterns of cannabis consumption in this population. Thus, this study aimed to assess the prevalence of cannabis consumption among patients with IRD in Germany just after legalisation and to analyse its associations with demographic and clinical factors, acceptance, and physician experience with prescription. Methods: Two surveys were performed on patients with IRD at 2 centres and on physicians treating these diseases. Patients and physicians were questioned about cannabis use, disease-related factors, treatments, and their experience with MC prescription. Results: Of 651 patients, 3% reported current and 12% past cannabis consumption. Cannabis use was higher among young men ( Conclusions: The high acceptance and reported efficacy of cannabis among patients with IRD likely anticipate an increase in MC consumption in Europe. Our data highlight the need for dedicated trials to define the indications of MC and to improve the education of physicians and patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.